Fractyl Health, Inc.

Snapshot

Fractyl Health is a pre-revenue biotech developing a procedural therapy for diabetes and obesity. FY 2025 revenue was $0, with a $141.0M net loss and $90.3M burned from operations.

What's Happening Right Now

• Fri 16th Oct '26 · Clinical trial: Fractyl's REMAIN-1 pivotal study hit its six-month weight-regain endpoint with strong statistical significance, and the company now plans an FDA De Novo filing in late Q4 2026, targeting a possible 2028 launch.
• Fri 16th Oct '26 · Analyst rating: Sell-side coverage settled on a consensus 'Hold' rating, made up of one sell, one hold, and three buy recommendations.
• Thu 1st Oct '26 · Reverse split: Fractyl completed a 1-for-12 reverse stock split effective Oct 2, 2026, a move typically used to stay compliant with Nasdaq's minimum share price rule.
• Thu 24th Sep '26 · Shareholder vote: On Sep 24, 2026, stockholders approved giving the board discretion to set the reverse-split ratio anywhere from 1-for-5 to 1-for-15.
• Mon 6th Apr '26 · ATM sale: Sold $22K net through its at-the-market program.
• Wed 31st Dec '25 · ATM sale: Sold $6.78M net / 392K shares through its at-the-market program, as stated for Jan 1, 2025 to Dec 31, 2025.
• Wed 12th Nov '25 · Warrants: Issued warrants.